Navigation Links
Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
Date:11/24/2011

THE HAGUE, November 24, 2011 /PRNewswire/ --

ProQares - a leading provider of testing, evaluation and certification services for protective equipment against chemical hazards - announced today a partnership with U.S.-based Rapid Pathogen Screening, Inc. (RPS®) - a leading developer of point-of-care diagnostic tests, to deploy the RPS chemical nerve agent detector in numerous countries throughout the European and Asia Pacific regions.  

The RPS chemical nerve agent detector is the first-of-its-kind point-of-care diagnostic test for human exposure to chemical poisons in the blood, including Soman, Sarin, Tabun, and VX, and is capable of detecting low-level chemical nerve agent exposure in 10 minutes or less with only a simple finger-stick blood sample.

"The partnership with RPS complements ProQares' mission to contribute to the protection of humans against toxic threats by providing fast and reliable test results," said Jack van Hoof, Managing Director of ProQares. "Through the partnership, ProQares will support RPS in marketing the RPS chemical nerve agent detector to its worldwide network of government and industrial organizations."

"This partnership will accelerate the deployment of this break-through technology and ensure that governments and other organizations charged with protecting the public from a chemical weapons attack have the most sophisticated tools available," said Robert Van Dine, Chief IP and Government Affairs Officer for RPS.

In June, in his address to the NATO Conference on WMD Arms Control, Disarmament and Non-Proliferation, Ambassador Ahmet Uzümcü, director-general of the Organisation for the Prohibition of Chemical Weapons (OPCW), focused NATO on his concern that "the future use of chemical weapons in a conventional military sense is remote. The misuse, on the other hand, of toxic chemicals, especially in an asymmetric sense, appears to be the more likely scenario."

A single chemical attack in an urban commercial or residential setting can result in tens of thouy" timex="11/24/2011 2:37:52 AM" dirsub="(sands of people that require immediate d...)" id="22399" index="medicine" dir="Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally" dir2="Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Inter..." keywords1=",medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology" keywords="Leading,Chemical,Weapons,Preparedness,Companies,Announce,Partnership,to,Deploy,Break-through,Diagnostic,Test,Internationally" description="sands of people that require immediate diagnosis and treatment. Treatm...In early 2012 RPS expects to apply the CE mark to the RPS chemical nerve agent detector and begin d... ..." url=u&"/medicine-technology-1/Leading-Chemical-Weapons-Preparedness-Companies-Announce-Partnership-to-Deploy-Break-through-Diagnostic-Test-Internationally-22399-2/" title="Leading%20Chemical%20Weapons%20Preparedness%20Companies%20Announce%20Partnership%20to%20Deploy%20Break-through%20Diagnostic%20Test%20Internationally" %> Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Inter... ( THE HAGUE November 24 2011 /- Pro...)

Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
Date:11/24/2011

sands of people that require immediate diagnosis and treatment. Treatment for chemical weapon nerve agent exposure often is most effective within the first 40 minutes. The RPS chemical nerve agent detector responds to this need by providing a rapid, accurate and cost-effective diagnosis at the point-of-care.

In early 2012, RPS expects to apply the CE mark to the RPS chemical nerve agent detector and begin discussions with the U.S. Food and Drug Administration to bring it to market in the United States. The product is not currently CE-marked and is not yet available for sale in the United States.


'/>"/>
SOURCE ProQares
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
2. Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process
3. United Spinal Secures Leading Public Policy and Durable Medical Equipment Specialist: Alex Bennewith is New Director of Government Relations
4. Leading Health Organizations and Patient Groups Call for 20 Percent Reduction in Fractures by 2020
5. Patients at Risk for Hepatitis B Are Not Adequately Screened Before Receiving Chemotherapy Leading to the Preventable Reactivation of Hepatitis B Infection
6. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
7. Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar
8. American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville
9. Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for Use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search
10. Phreesia Continues to Enhance its Market-Leading Eligibility and Benefits Verification Process for Medical Practices
11. CADCA and Leading Makers of OTC Medicines Call Communities to Action During National Medicine Abuse Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):